Back to search results

Elecoglipron and Dapagliflozin for Type 2 Diabetes

This study is testing two medications, elecoglipron and dapagliflozin, alone or in combination, to see how well they work and if they are safe for adults with Type 2 Diabetes Mellitus (T2DM). You might be able to join if you have T2DM that isn't well-controlled with your current treatment or lifestyle changes, and your Hemoglobin A1c (HbA1c) is between 7% and 10.5%. The main goal is to see how much your HbA1c changes over 40 weeks. The study is planning to enroll about 800 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 800 participants. It compares elecoglipron alone or with dapagliflozin against a placebo (an inactive substance).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your Hemoglobin A1c (HbA1c) will be measured from the start of the study until Week 40.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07662044

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

Recruiting
PHASE3Ages 18+InterventionalTreatment
AstraZeneca
~800 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:ElecoglipronDapagliflozinElecoglipron-matched placeboDapagliflozin-matched placebo

At a glance

Recruiting sites
4 of 150 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in Hemoglobin A1c (HbA1c)
Measured over Baseline to Week 40

Conditions

Type 2 Diabetes Mellitus

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

150 sites across 29 states
China39
Greece10
Japan10
South Africa10
Taiwan10
Argentina8
Hungary7
Slovakia7

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion

Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (New York Heart Association IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

What this trial measures

  • Change from baseline in Hemoglobin A1c (HbA1c)Baseline to Week 40